Minoryx is a clinical stage biotech company leading the development of new therapies for orphan CNS diseases with a high unmet medical need. The company’s lead program is MIN-102, currently in clinical trials for X-linked Adrenoleukodystrophy and Friedreich’s Ataxia.
The Minoryx team is made up of a group of experts with several decades of experience in biotech and pharma. The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011 and has operations both in Spain (Mataró, Barcelona) and Belgium (Charleroi Brussels South Biopark).